| Identification | Back Directory | [Name]
3-Pyridinecarboxamide, 2-amino-5-[4-[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]amino]-2-ethylphenyl]-N-(1-methylethyl)- | [CAS]
2616821-91-9 | [Synonyms]
3-Pyridinecarboxamide, 2-amino-5-[4-[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]amino]-2-ethylphenyl]-N-(1-methylethyl)- | [Molecular Formula]
C25H26F2N4O3 | [MOL File]
2616821-91-9.mol | [Molecular Weight]
468.5 |
| Chemical Properties | Back Directory | [Boiling point ]
681.5±55.0 °C(Predicted) | [density ]
1.311±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (533.62 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.62±0.46(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC50s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model[1]. | [Biological Activity]
PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC50s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model[1].
PERK-IN-5 (compound 28) (10-48 μM) is relatively stable in both human and dog hepatocytes and is characterized with long half-lives[1].
PERK-IN-5 (3-100 mg/kg; p.o.; 0.25-24 hours) has robust pharmacokinetics in CD1 mice, with Cmax of 3353 ng/mL, AUC0-last of 5153 h*ng/mL, and bioavailability of 70%[1].PERK-IN-5 (3 or 10 mg/kg; p.o.; twice daily, for 28 days) has statistically significant tumor growth inhibition[1]. | [in vivo]
PERK-IN-5 (3-100 mg/kg; p.o.; 0.25-24 hours) has robust pharmacokinetics in CD1 mice, with Cmax of 3353 ng/mL, AUC0-last of 5153 h*ng/mL, and bioavailability of 70%[1].
PERK-IN-5 (3 or 10 mg/kg; p.o.; twice daily, for 28 days) has statistically significant tumor growth inhibition[1]. | Animal Model: | Female CD1 mice[1] (Pharmacokinetics) | | Dosage: | 3, 10, 30 and 100 mg/kg | | Administration: | p.o.; 0.25-24 hours | | Result: | Showed robust pharmacokinetics with Cmax of 3353 ng/mL, AUC0-last of 5153 h*ng/mL, and bioavailability of 70%. |
| Animal Model: | BALB/c nude female mice (inoculated subcutaneously with 786-O tumor cells)[1] | | Dosage: | 3 or 10 mg/kg | | Administration: | p.o.; twice daily, for 28 days | | Result: | Showed statistically significant tumor growth inhibition. |
| [References]
[1]. Calvo V, et al. Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors. Bioorg Med Chem Lett. 2021;43:128058. |
|
|